Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases
NCT ID: NCT01248429
Last Updated: 2012-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
154 participants
OBSERVATIONAL
2010-11-30
2011-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)
NCT00812864
Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors
NCT00613145
Reduction of Cancer Related Fatigue in Patients During TKI Therapy
NCT01645150
Current Status of BTKi Treatment for CLL/SLL in China
NCT06508684
A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer
NCT00535522
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient treated by TKI
Any patient with solid tumor and treated by Thyrosine Kinase Inhibitor for at least 1 week
CPK dosage
CPK dosage during a blood sample realized at least one week after the begining of the treatment
Clinical exam
Examination of the patient for myalgia, cramps, medical history and concomitant medication
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CPK dosage
CPK dosage during a blood sample realized at least one week after the begining of the treatment
Clinical exam
Examination of the patient for myalgia, cramps, medical history and concomitant medication
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient examined AND with a routine blood test planned
* Patient informed of procedure for the study who was not opposed to it
Exclusion Criteria
* Patient no treated by inhibitor of thyrosine kinase or for less than 1 week
* Patients with no routine blood laboratory tests planned
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Oscar Lambret
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Antoine ADENIS, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Centre Oscar Lambret
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Paul Papin
Angers, , France
Hôpital Jean Minjoz
Besançon, , France
CHU Bordeaux
Bordeaux, , France
Institut Bergonié
Bordeaux, , France
Centre François Baclesse
Caen, , France
Centre Jean Perrin
Clermont-Ferrand, , France
Hôpital Henri Mondor - APHP
Créteil, , France
Centre Oscar Lambret
Lille, , France
CHU Limoges
Limoges, , France
Hôpital Edouard Herriot
Lyon, , France
Centre Léon Bérard
Lyon, , France
Institut Paoli Calmettes
Marseille, , France
Centre Val d'Aurelle
Montpellier, , France
Centre Antoine Lacassagne
Nice, , France
Hôpital Saint-Louis - APHP
Paris, , France
Hôpital Cochin - APHP
Paris, , France
Hôpital Tenon - APHP
Paris, , France
Institut Curie
Paris, , France
Institut Jean Godinot
Reims, , France
CHU Robert Debré
Reims, , France
Centre Eugène Marquis
Rennes, , France
Centre Henri Becquerel
Rouen, , France
Centre René Huguenin
Saint-Cloud, , France
Institut de Cancérologie de la Loire
Saint-Priest-en-Jarez, , France
Institut Claudius Régaud
Toulouse, , France
Centre Alexis Vautrin
Vandœuvre-lès-Nancy, , France
Institut Gustave Roussy
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TKI-CPK 1003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.